• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hepatology Acute Liver Injury in COVID-19: Prevalence and Association With Clinical Outcomes in a Large US Cohort

tetano

Editor, Senior Moderator
Hepatology


. 2020 May 30.
doi: 10.1002/hep.31404. Online ahead of print.
Acute Liver Injury in COVID-19: Prevalence and Association With Clinical Outcomes in a Large US Cohort


Meaghan M Phipps[SUP] 1 [/SUP], Luis H Barraza[SUP] 1 [/SUP], Elijah D LaSota[SUP] 2 [/SUP], Magdalena E Sobieszczyk[SUP] 2 [/SUP], Marcus R Pereira[SUP] 2 [/SUP], Elizabeth X Zheng[SUP] 1 3 [/SUP], Alyson N Fox[SUP] 1 3 [/SUP], Jason Zucker[SUP] 2 [/SUP], Elizabeth C Verna[SUP] 1 3 [/SUP]



Affiliations

Abstract

Background & aims: Coronavirus disease 2019 (COVID-19) has been associated with acute liver injury manifested by increased liver enzymes in reports worldwide. Prevalence of liver injury and associated clinical characteristics are not well-defined. We aim to identify the prevalence of and risk factors for development of COVID-19 associated acute liver injury in a large cohort in the United States.
Approach & results: In this retrospective cohort study, all patients who underwent SARS-CoV-2 testing at three hospitals in the NewYork-Presbyterian network were assessed. Of 3381 patients, 2273 tested positive and had higher initial and peak ALT than those who tested negative. Acute liver injury was categorized as mild if alanine aminotransferase (ALT) was > upper limit of normal (ULN) but < two times ULN, moderate if ALT was between two and five times ULN, and severe if ALT was > five times ULN. Among patients who tested positive, 45% had mild, 21% moderate, and 6.4% severe liver injury. In multivariable analysis, severe acute liver injury was significantly associated with elevated inflammatory markers including ferritin (OR 2.40, p<0.001) and IL-6 (OR 1.45, p=0.009). Patients with severe liver injury had a more severe clinical course, including higher rates of ICU admission (69%), intubation (65%), renal replacement therapy (33%), and mortality (42%). In multivariable analysis, peak ALT was significantly associated with death or discharge to hospice (OR 1.14, p=0.044), controlling for age, body mass index, diabetes, hypertension, intubation, and renal replacement therapy.
Conclusion: Acute liver injury is common in patients who test positive for SARS-CoV-2, but is most often mild. However, among the 6.4% of patients with severe liver injury, a severe disease course should be anticipated.

Keywords: SARS-CoV-2; coronavirus; hepatitis.
 
Back
Top Bottom